ArticleJournal of acquired immune deficiency syndromes (1999)2026
Brief Report: Long-Acting Injectable PrEP Can Substantially Reduce HIV Incidence in Los Angeles County: A Simulation Study.
Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough oral pre-exposure prophylaxis (PrEP) has been instrumental in decreasing HIV incidence, its daily dosing regimen poses adherence challenges. Using an agent-based network model informed by empirical data, we simulate the impact of introducing long-acting injectable (LAI) PrEP among young Black men who have sex with men (YBMSM) in Los Angeles County, a group disproportionately affected by HIV.
settingComputer simulations using an agent-based network model.
methodsWe modeled HIV transmission among YBMSM over 10 years under scenarios varying the proportion of PrEP users opting for LAI instead of oral medications and adherence levels to LAI retention. The model was calibrated with empirical data and included dynamic sexual networks, HIV progression, and biomedical interventions.
resultsModeling showed that LAI PrEP substantially reduced HIV incidence and prevalence over 10 years compared with oral PrEP alone. Scenarios with LAI retention (ie, continued use across bimonthly dosing cycles) rates of 60% or higher resulted in reductions comparable with or exceeding those achieved by oral PrEP, with up to a 45% decrease in HIV incidence observed when all PrEP users switched to LAI and retention reached 85%.
conclusionsLong-acting injectable PrEP offers significant potential to advance HIV prevention efforts among YBMSM by addressing adherence challenges inherent to oral PrEP. Integrating LAI into public health initiatives may yield substantial reductions in HIV incidence, contributing to ending the HIV epidemic among this high-priority population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.